Please assess the completion status of the following clinical trial:

Trial Title: Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-85~* NIHSS score 8-20~* Stroke is ischemic in origin, supratentorial, and radiologically confirmed~* Patient is 24-48 hours from time of stroke onset when the first dose of NTx®-265 therapy is administered~* Reasonable expectation of availability to receive the full 9 day NTx®- 265 therapy and subsequent follow-up visits~* Reasonable expectation that patient will receive standard post-stroke physical, occupational, speech, and cognitive therapy as indicated~* Female patient is either not of childbearing potential or agrees to use two of the effective separate non-hormonal forms of contraception throughout the study~Exclusion Criteria:~* Patients presenting with lacunar, hemorrhagic and/or brain stem stroke~* Patients who have received tissue plasminogen activator (tPA)following the index stroke~* Patients classified as comatose~* Women who have tested positive for pregnancy, or are breast-feeding, or are not using a birth control~* Serum hemoglobin \> 16 grams(g)/deciliter (dL)(males) or \> 14 g/dL (females); or platelet count \> 400,000/cubic millimeters(mm3)~* Advanced liver, kidney, cardiac, or pulmonary disease~* Elevated serum bilirubin,alkaline phosphatase, aspartate aminotransferase (AST) or alanine transaminase (ALT),creatinine, or prostate-specific antigen (PSA) levels~* Patients with a known history of hypercoagulability~* Expected survival \< 1 year~* Allergy or other contraindication to hCG or EPO~* A known diagnosis of cancer in the previous 5 years~* Uncontrolled hypertension~* Use of either hCG or epoetin alfa within the previous 90 days~* Any condition known to elevate hCG~* Patients with a pre-stroke/pre-morbid modified Rankin Score (mRS)≥ 2~* Any patients not living independently~* Any other medical condition or degree of stroke such that, in the investigator's opinion, the patient should not be included in the trial~* With the exception of the qualifying stroke, any other stroke within the previous 3 months~* Patients who cannot take anti-platelet or anti-coagulant therapy~* Pre-existing and active major psychiatric or other chronic neurological disease~* Alcohol abuse or have a history of substance abuse or dependency within 12 months prior to the study~* Currently participating in another investigational study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- NTx®-265 Low Dose (Type: EXPERIMENTAL): hCG 385 µg (10,000 international unit \[IU\]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation
- NTx®-265 Medium Dose (Type: EXPERIMENTAL): hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
- NTx®-265 High Dose (Type: EXPERIMENTAL): hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
- Saline Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).